Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Friday. $92.42 million flowed into the stock on the tick-up and $222.61 million flowed out of the stock on the tick-down, for a money net flow of $130.19 million out of the stock. Of all companies tracked, Johnson & Johnson had the 9th highest net out-flow for the day. Johnson & Johnson traded up $2.11 for the day and closed at $132.02
A number of analysts have commented on the stock. Vetr upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating and set a $152.28 price objective for the company in a report on Monday, February 5th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. BTIG Research reiterated a “sell” rating and issued a $110.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $146.16.
The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The firm has a market capitalization of $354,670.00, a PE ratio of 24.31, a price-to-earnings-growth ratio of 2.18 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the company posted $1.58 EPS. research analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.55%. Johnson & Johnson’s payout ratio is currently 61.88%.
In related news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.19% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after buying an additional 3,023,110 shares in the last quarter. BlackRock Inc. lifted its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after buying an additional 130,437 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Johnson & Johnson by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 30,521,157 shares of the company’s stock worth $4,256,109,000 after buying an additional 939,488 shares in the last quarter. Finally, FMR LLC lifted its holdings in Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after buying an additional 1,509,745 shares in the last quarter. 65.58% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Traders Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/23/traders-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.